Loading...
XSHG
603520
Market cap670mUSD
Sep 30, Last price  
10.89CNY
Name

Zhejiang Starry Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
2.03
EPS
—
Div Yield, %
0.46%
Shrs. gr., 5y
4.48%
Rev. gr., 5y
12.42%
Revenues
2.35b
+7.02%
506,582,117574,710,788685,904,772658,482,615695,660,000672,945,253710,939,018890,470,7811,308,841,6351,367,087,2411,999,916,8882,131,239,9882,195,986,1542,350,224,699
Net income
-49m
L
67,567,06535,784,63663,657,74467,704,20868,944,11876,121,53983,116,97493,676,375170,331,965238,729,340323,754,754044,232,089-49,098,979
CFO
194m
+319.51%
-41,072,600103,342,43174,993,069144,000,55994,879,3667,679,73418,104,512191,835,586246,768,072174,479,180508,839,385046,126,089193,502,193
Dividend
Sep 09, 20240.05 CNY/sh

Profile

Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products comprise levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is based in Xianju, China.
URL
http://www.starrypharm.com
IPO date
Mar 09, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,350,225
7.02%
2,195,986
3.04%
2,131,240
6.57%
Cost of revenue
2,199,583
1,939,744
1,891,012
Unusual Expense (Income)
NOPBT
150,642
256,242
240,228
NOPBT Margin
6.41%
11.67%
11.27%
Operating Taxes
(8,068)
799
6,521
Tax Rate
0.31%
2.71%
NOPAT
158,710
255,443
233,707
Net income
(49,099)
-211.00%
44,232
 
Dividends
(128,425)
(68,251)
(122,438)
Dividend yield
3.61%
1.42%
1.83%
Proceeds from repurchase of equity
(10,183)
BB yield
0.21%
Debt
Debt current
1,985,946
1,855,028
2,106,641
Long-term debt
726,757
734,480
676,929
Deferred revenue
101,948
94,410
Other long-term liabilities
91,665
1
Net debt
1,953,215
1,894,932
1,986,069
Cash flow
Cash from operating activities
193,502
46,126
CAPEX
(480,619)
(266,225)
Cash from investing activities
(490,735)
(255,560)
Cash from financing activities
299,029
83,011
363,584
FCF
(617,245)
252,969
(529,464)
Balance
Cash
603,355
565,157
662,440
Long term investments
156,134
129,418
135,061
Excess cash
641,977
584,776
690,939
Stockholders' equity
1,010,802
806,055
994,327
Invested Capital
4,712,218
3,855,281
3,948,958
ROIC
3.70%
6.55%
6.46%
ROCE
2.81%
5.77%
5.18%
EV
Common stock shares outstanding
409,158
340,247
342,252
Price
8.69
-38.28%
14.08
-28.05%
19.57
-57.85%
Market cap
3,555,584
-25.78%
4,790,676
-28.47%
6,697,864
-57.81%
EV
5,515,091
6,691,903
8,689,907
EBITDA
372,814
435,796
400,670
EV/EBITDA
14.79
15.36
21.69
Interest
102,516
108,653
92,600
Interest/NOPBT
68.05%
42.40%
38.55%